View Older Stories View More Recent Stories

Mar 3, 2020 07:00AM Obsidian Therapeutics Appoints Anders Götzsche to Board of Directors
Mar 2, 2020 07:00AM Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing
Feb 26, 2020 08:00AM Cadent Therapeutics to Present at the Cowen 40th Annual Health Care Conference
Feb 26, 2020 07:00AM Triplet Therapeutics to Present at Cowen 40th Annual Health Care Conference
Feb 19, 2020 04:05PM Cadent Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Feb 18, 2020 09:52PM Form 4 AVROBIO, Inc. For: Feb 13 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
Feb 13, 2020 05:01PM Form SC 13G/A Magenta Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Feb 13, 2020 05:01PM Form SC 13G Akero Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 11, 2020 05:30PM Form 13F-NT Atlas Venture Associates For: Dec 31
Feb 11, 2020 05:30PM Form 13F-NT Atlas Venture Associates For: Dec 31
Feb 11, 2020 05:30PM Form 13F-NT ATLAS VENTURE FUND VI For: Dec 31
Feb 11, 2020 05:29PM Form 13F-HR Atlas Venture Advisors, For: Dec 31
Feb 11, 2020 05:28PM Form 13F-HR Atlas Venture Associates For: Dec 31
Feb 10, 2020 07:50PM Form 4 Akero Therapeutics, Inc. For: Feb 07 Filed by: Atlas Venture Opportunity Fund I, L.P.
Feb 6, 2020 04:05PM Cadent Therapeutics Announces Poster Presentation at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress
Feb 6, 2020 08:00AM Dyne Therapeutics Expands Leadership Team with Key Hires
Feb 4, 2020 03:15PM Form SC 13G/A Translate Bio, Inc. Filed by: Atlas Venture Fund VIII, L.P.
Feb 4, 2020 03:13PM Form SC 13G BICYCLE THERAPEUTICS Filed by: Atlas Venture Fund VIII, L.P.
Feb 4, 2020 03:11PM Form SC 13G/A ZAFGEN, INC. Filed by: Atlas Venture Fund VII L P
Feb 4, 2020 03:01PM Form SC 13G/A Unum Therapeutics Inc. Filed by: Atlas Venture Fund IX, L.P.
Feb 4, 2020 02:59PM Form SC 13G/A Surface Oncology, Inc. Filed by: Atlas Venture Fund IX, L.P.
Feb 4, 2020 02:57PM Form SC 13G/A Spero Therapeutics, Inc. Filed by: Atlas Venture Fund IX, L.P.
Jan 28, 2020 07:00AM Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid Tumors
Jan 27, 2020 02:00AM Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
Jan 27, 2020 02:00AM Arix Co-founds Quench Bio With Series A Financing
Jan 23, 2020 07:00AM Cadent Therapeutics Announces FDA Acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)
Jan 13, 2020 08:00AM Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer
Jan 10, 2020 07:10AM Generation Bio to Present at 38th Annual J.P. Morgan Healthcare Conference
Jan 10, 2020 07:00AM Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
Jan 8, 2020 06:03AM Karl Naegler joins Wellington Partners as Managing Partner
Jan 2, 2020 05:19PM Form 4 Akero Therapeutics, Inc. For: Dec 31 Filed by: Atlas Venture Fund XI, L.P.
Dec 19, 2019 05:35PM Form 4 Akero Therapeutics, Inc. For: Dec 17 Filed by: Atlas Venture Fund XI, L.P.
Dec 17, 2019 08:30AM Indalo Therapeutics Appoints Healthcare Industry Veteran and Serial Entrepreneur Michael Heffernan as Board Chair
Dec 17, 2019 06:00AM Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders
Dec 10, 2019 05:30PM Cadent Therapeutics Announces Poster Presentation at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
Dec 3, 2019 07:00AM Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of Growth
Dec 2, 2019 07:00AM Cadent Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference
Dec 2, 2019 06:30AM IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer
Nov 25, 2019 05:17PM Form SC 13D Replimune Group, Inc. Filed by: Atlas Venture Fund X, L.P.
Nov 20, 2019 05:50PM Form 3 Replimune Group, Inc. For: Nov 18 Filed by: Atlas Venture Associates Opportunity I, L.P.
Nov 20, 2019 01:41PM New Research Demonstrates Second Direct Link Between Inflammasome Activation and Alzheimer's Disease
Nov 20, 2019 07:00AM Kymera Therapeutics Promotes Nello Mainolfi, PhD, to Chief Executive Officer
Nov 14, 2019 07:00AM Cadent Therapeutics to Present at Upcoming Investor Conferences
Nov 12, 2019 11:22AM Form 13F-HR Atlas Venture Associates For: Sep 30
Nov 12, 2019 11:21AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 12, 2019 11:21AM Form 13F-NT ATLAS VENTURE FUND VI For: Sep 30
Nov 12, 2019 11:20AM Form 13F-HR Atlas Venture Advisors, For: Sep 30
Nov 12, 2019 11:20AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 11, 2019 08:30AM Indalo Therapeutics Presents Phase 1 Clinical Trial Results for Lead Antifibrotic Drug Candidate IDL-2965
Nov 7, 2019 05:00AM Arkuda Therapeutics Closes $44M Series A Financing to Advance Novel Medicines Targeting Progranulin and Lysosomal Biology to Treat Neurodegenerative Diseases
View More Recent Stories View Older Stories